AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2861067
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg fenoterol and 0.5 mg ipratropium (group B)
Trial: 30913162
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (CM) 0.3 g·kg⋅d for 1 week (loading phase) and 5 g·d for 7 weeks (maintenance phase)
Trial: 19048243
Drug: Exogenous alkaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous alkaline phosphatase (AP) administered via 10-min IV infusions or 24-72 h continuous IV infusion (132.5-200 U kg(‐1) 24 h(‐1))
Trial: 19048243
Drug: Exogenous alkaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous alkaline phosphatase (AP) administered via 10-min IV infusions
Trial: 19048243
Drug: Exogenous alkaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous alkaline phosphatase (AP) administered via 24-72 h continuous IV infusion
Trial: 16870769
Drug: FPV plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPV plus LPV/RTV at 700 mg plus 400 mg/100 mg q12h simultaneously
Trial: 16870769
Drug: FPV/RTV at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPV/RTV at 700 mg/100 mg q12h plus LPV/RTV at 400 mg/100 mg q12h, with doses separated by 4 h
Trial: 16870769
Drug: FPV/RTV at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPV/RTV at 700 mg/100 mg q12h plus LPV/RTV at 400 mg/100 mg q12h, with doses separated by 12 h
Trial: 8462533
Drug: Lignocaine 0.39
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 0.39 mg kg‐1
Trial: 8462533
Drug: Lignocaine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 0.5 mg kg‐1
Trial: 8462533
Drug: Lignocaine 0.63
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 0.63 mg kg‐1
Trial: 8462533
Drug: Lignocaine 0.79
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 0.79 mg kg‐1
Trial: 8462533
Drug: Lignocaine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 1.0 mg kg‐1
Trial: 2579877
Drug: Topical flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical flurbiprofen (0.1%)
Trial: 30128853
Drug: L-menthol mouth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-menthol mouth rinse (0.01%)
Trial: 30128853
Drug: Ice ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice ingestion (1.25 g kg-1)
Trial: 26410392
Drug: Filtered sugarcane
RxNorm normalized name: Sugarcane
DrugBank: Sugarcane (DB10906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filtered sugarcane molasses concentrate (FMC) administered as an oral supplement before a meal, with varying doses (exact doses not specified)
Trial: 26410392
Drug: Placebo syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup (test meal 1)
Trial: 22665534
Drug: Six-drug combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six-drug combination (IVA plus carboplatin, epirubicin, and etoposide)
Trial: 9578178
Drug: Dipyridamole combined
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole combined with warfarin
Trial: 2682348
Drug: Dietary erucic
RxNorm normalized name: behenyl erucate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary erucic acid therapy
Trial: 123815
Drug: Analgesic tablets
RxNorm normalized name: Aspirin/Caffeine 400 MG-32 MG Oral Tablet [ANALGESIC TABLETS]
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic tablets
Trial: 25986648
Drug: Gantong Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gantong Granules (high-dose, medium-dose, low-dose)
Trial: 22066244
Drug: vitaprost plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitaprost plus (rectal suppositories), one suppository before going to bed 2 days before surgery and for 8 days after TUR, total course lasted for 10 days.
Trial: 22066244
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no vitaprost plus treatment).
Trial: 22066244
Drug: vitaprost plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitaprost plus (rectal suppositories).
Trial: 16484571
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and omeprazole for Helicobacter pylori infection
Trial: 16484571
Drug: Garlic supplement
RxNorm normalized name: Garlic 300 MG Oral Capsule [GARLIC SUPPLEMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic supplement (aged garlic extract and steam-distilled garlic oil)
Trial: 16484571
Drug: Vitamin supplement
RxNorm normalized name: Vitamin supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin supplement (vitamins E and C and selenium)
Trial: 15340534
Drug: Ganciclovir (GCV)
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir (GCV) + intravenous immunoglobulin (IVIG)
Trial: 11142413
Drug: Piroxicam 7.5
RxNorm normalized name: piroxicam 7.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 7.5 mg/day
Trial: 9771366
Drug: Control local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control local anaesthetic solution
Trial: 7836713
Drug: Octreotide (100‐micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100‐micrograms bolus with a 100‐micrograms/h infusion)
Trial: 3046465
Drug: Nalbuphine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (0.2 mg kg‐1)
Trial: 3046465
Drug: Pentazocine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (0.5 mg kg‐1)
Trial: 31062119
Drug: Maternal nut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal nut consumption during first pregnancy trimester (> 32 g/week)
Trial: 29018896
Drug: HYP extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYP extract (900 mg)
Trial: 25272653
Drug: Soybean (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean (100 mg)
Trial: 25272653
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg) plus Soybean (100 mg)
Trial: 18701556
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg every other week (eow) for 24 weeks, then switched to open-label adalimumab 40 mg eow.
Trial: 17642246
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of biologics
Trial: 15229669
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in a warm climate (Lanzarote)
Trial: 15229669
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in Norway (Control)
Trial: 12395803
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 2.0 mg daily
Trial: 12395803
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 0.2 mg daily
Trial: 10457878
Drug: Diltiazem (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (0.2 mg kg‐1)
Trial: 10457878
Drug: Metoprolol (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (0.02 mg kg‐1)
Trial: 10457878
Drug: Verapamil (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (0.05 mg kg‐1)
Trial: 7788574
Drug: Double-blind oral
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind oral challenge with food additives (monosodium glutamate, tartrazine, sulfites, erythrosine, paraoxybenzoate, sodium benzoate, lactose, aspirin, and annate) under placebo control
Trial: 7788574
Drug: Skin-prick tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin-prick tests and patch tests
Trial: 1972605
Drug: Ranitidine (histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (histamine H2-receptor antagonist)
Trial: 417376
Drug: Ethchlorvynol 500
RxNorm normalized name: ethchlorvynol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethchlorvynol 500 mg for 14 days
Trial: 417376
Drug: Ethchlorvynol 500
RxNorm normalized name: ethchlorvynol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethchlorvynol 500 mg
Trial: 24517082
Drug: Hydrocodone extended
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone extended release (20-100 mg every 12 hours)
Trial: 11374333
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg olanzapine
Trial: 11844887
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg olanzapine
Trial: 11844887
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg olanzapine
Trial: 11844887
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg or 10 mg olanzapine
Trial: 2260873
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy (adreno‐oophorectomy, H)
Trial: 2260873
Drug: Chemotherapy (FAC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (FAC, C)
Trial: 2260873
Drug: Chemoendocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoendocrine therapy (FAC + tamoxifen, H'C)
Trial: 2260873
Drug: Chemoendocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoendocrine therapy (FAC + adreno‐oophorectomy, HC)
Trial: 30242948
Drug: liraglutide 0.6
RxNorm normalized name: liraglutide 0.6 mg/0.1 mL (18 mg/3 mL) SUBCUT PEN INJECTOR (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 0.6 mg daily, titrated to 1.2 mg after the first week
Trial: 28591244
Drug: Probiotic fermented
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic fermented milk beverage (150 mL for 60 days)
Trial: 28591244
Drug: Non-probiotic milk
RxNorm normalized name: PROBIOTIC
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-probiotic milk (150 mL for 60 days)
Trial: 24084800
Drug: Usual obstetric
RxNorm normalized name: chlorhexidine gluconate Topical Cream [Hibitane Obstetric]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual obstetric care and osteopathic manual treatment (UOBC+OMT)
Trial: 24084800
Drug: Usual obstetric
RxNorm normalized name: chlorhexidine gluconate Topical Cream [Hibitane Obstetric]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual obstetric care and sham ultrasound therapy (UOBC+SUT)
Trial: 18851771
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy for psychosis (CBTp)
Trial: 16778608
Drug: 2 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL/kg of bw of a nonionic contrast agent (300 mg I/mL) injected at 4 mL/sec
Trial: 16778608
Drug: 2 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL/kg of bw of a nonionic contrast agent (300 mg I/mL) injected at 3 mL/sec
Trial: 14534763
Drug: Immunoglobulin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin (2 g/kg) and aspirin (80-100 mg/kg/day) given before day 5 of illness
Trial: 14534763
Drug: Immunoglobulin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin (2 g/kg) and aspirin (80-100 mg/kg/day) given on or after day 5 of illness
Trial: 12374709
Drug: TSA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSA with 20 mL of 1.5% lidocaine (TSA-Lido)
Trial: 12374709
Drug: i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion with 300 mg of lidocaine (i.v.-Lido)
Trial: 10215748
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir 1000 mg every 8h
Trial: 10215748
Drug: Oral trimethoprim
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral trimethoprim 200 mg once daily
Trial: 10215748
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs concomitantly
Trial: 8642904
Drug: Atropine (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.03 mg/kg)
Trial: 8642904
Drug: Atenolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (10 mg)
Trial: 2338194
Drug: Lovastatin, 40
RxNorm normalized name: Lovastatin, 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin, 40 mg, twice a day
Trial: 2338194
Drug: Ursodeoxycholic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid, 10 mg/kg per day
Trial: 2338194
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lovastatin and ursodeoxycholic acid
Trial: 29959787
Drug: Elobixibat 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elobixibat 2.5 mg
Trial: 29959787
Drug: Elobixibat 5
RxNorm normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Elobixibat 5 mg
Trial: 28840422
Drug: Elobixibat 10
RxNorm normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Elobixibat 10 mg
Trial: 28840422
Drug: Elobixibat 15
RxNorm normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Elobixibat 15 mg
Trial: 29959787
Drug: Elobixibat 20
RxNorm normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Elobixibat 20 mg
Trial: 26378033
Drug: Imatinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (200 mg daily)
Trial: 26378033
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m2 i.v. weekly × 4 doses, repeatable after 3 months)
Trial: 25454967
Drug: Acupoint pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint pressure therapy (APT)
Trial: 25454967
Drug: Collateral meridian
RxNorm normalized name: sibutramine hydrochloride Oral Capsule [Meridia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collateral meridian therapy (CMT)
Trial: 20569776
Drug: Unassisted bibliotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unassisted bibliotherapy (n=20) with a scheduled follow‐up telephone interview, no therapist contact, treatment phase lasted for 10 weeks.
Trial: 18723851
Drug: Nitroglycerin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin administration during head-up tilt test (HUT)
Trial: 18723851
Drug: Head-up tilt
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Head-up tilt test without nitroglycerin administration
Trial: 18723851
Drug: Head-up tilt
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Head-up tilt test before nitrate administration
Trial: 15709995
Drug: Beidellitic montmorillonite
RxNorm normalized name: Montmorillonite
DrugBank: Montmorillonite (DB13654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beidellitic montmorillonite (3 g, t.d. for 8 weeks)
Trial: 11799340
Drug: Risperidone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.5 to 6.0 mg/day, median dose 2.5 mg/day)
Trial: 20856184
Drug: venlafaxine extended
RxNorm normalized name: Desvenlafaxine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: venlafaxine extended release (75 to 325 mg daily)
Trial: 10189453
Drug: Anticholinergic agent
RxNorm normalized name: ANTICHOLINERGIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic agent
Trial: 1326708
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oestradiol valerate (E2V)
Trial: 1326708
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oestradiol valerate combined with 1 mg cyproterone acetate (E2V+CPA)
Trial: 16359587
Drug: Osteopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic treatment
Trial: 26999966
Drug: Corticosteroids (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (40 mg methylprednisolone)
Trial: 21252702
Drug: Alcohol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (1.0 g/kg body weight)
Trial: 17063660
Drug: Small-particle formulations
RxNorm normalized name: Smallpox (Vaccinia) Vaccine, Live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-particle formulations of ICSs
Trial: 17063660
Drug: Reduced oropharyngeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced oropharyngeal deposition and prodrug administration
Trial: 10953973
Drug: Dose-escalated CHOP
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-escalated CHOP (6 cycles with cyclophosphamide 1.5 g/m2 and doxorubicin 70 mg/m2)
Trial: 3286363
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of acarbose
Trial: 29685011
Drug: Glucocorticoids in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoids in combination with ursodesoxycholic acid
Trial: 19888948
Drug: C.E.R.A. twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C.E.R.A. twice every week (Q2W)
Trial: 19888948
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (once weekly or Q2W)
Trial: 16102549
Drug: Transdermal patch
RxNorm normalized name: TRANSDERMAL PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patch (20 microg EE/day)
Trial: 16102549
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (30 microg EE)
Trial: 7631288
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (EGb 761) administered orally while fasting
Trial: 7631288
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (EGb 761) administered orally after a standard meal
Trial: 7631288
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (EGb 761) administered intravenously
Trial: 2921098
Drug: Simvastatin (MK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (MK 733) 20 mg and 40 mg daily for 104 weeks
Trial: 22132709
Drug: Povidone iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone iodine plus bepanthenol cream (standard practice)
Trial: 15089819
Drug: tolterodine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine (2 mg, BID) + duloxetine (40 mg, BID)
Trial: 15089819
Drug: tolterodine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine (2 mg, BID) + duloxetine placebo (BID)
Trial: 9587128
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate tablets (45 mg, three times a day)
Trial: 9587128
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (three times a day)
Trial: 2669092
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g L-tryptophan
Trial: 2669092
Drug: 2.4 g
RxNorm normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g L-tryptophan
Trial: 2669092
Drug: L-tryptophan (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (both doses)
Trial: 23616514
Drug: L-tryptophan (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (all doses)
Trial: 23903649
Drug: Control (original‐lesion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (original‐lesion control, intra‐oral controls)
Trial: 22153532
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (1 g bid for 10 days)
Trial: 22153532
Drug: Placebo (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sodium bicarbonate 1 g bid for 10 days)
Trial: 19898719
Drug: Acetone-containing bonding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetone-containing bonding agent (control group)
Trial: 17998456
Drug: Enoxaparin 1
RxNorm normalized name: ENOXAPARIN 100MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1 mg/kg twice daily (group 1)
Trial: 17998456
Drug: Enoxaparin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 0.5 mg/kg twice daily (group 2)
Trial: 17998456
Drug: Warfarin continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin continued (group 3)
Trial: 14726422
Drug: Glutathione aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione aerosol (300 or 450 mg, thrice daily for 14 days)